Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Trial Profile

A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RX 0201 (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2019 Results of the phase II part of the study (n=11) presented at the 2019 Genitourinary Cancers Symposium
    • 06 Feb 2019 According to a Rexahn Pharmaceuticals media release, data will be presented at the 2019 ASCO Genitourinary Cancers Symposium.
    • 08 Feb 2018 According to a Rexahn Pharmaceuticals media release, the company plans to discontinue the internally funded programs of Archexin in Renal Cell Carcinoma and will cease enrollment of this trial. Patients currently enrolled in the trial will continue to be followed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top